A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

Pfizer

Status and phase

Completed

Phase 2

Conditions

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Colorectal Neoplasms

Pancreatic Neoplasms

Treatments

Drug: CI-1040

Study type

Interventional

Funder types

Industry

Identifiers

NCT00034827

1040-000-002

Details and patient eligibility

About

CI-1040 is an experimental drug that is being tested in patients who have advanced colorectal and lung cancer who failed no more than one prior chemotherapy regimen, breast cancer who have failed no more than 2 prior regimens and in patients with pancreatic cancer who have received no prior chemotherapy. CI-1040 is taken orally twice daily with meals. Patients are required to have blood tests periodically while receiving treatment and will be monitored closely throughout the trial for possible side effects and for response.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who are at least 18 years or older who have pathological or hiostological confirmation of colorectal, nonsmall cell lung cancer, breast, or pancreas cancer.
No more than 1 prior chemo for lung or colon cancer, no more than 2 for breast no prior chemotherapy for pancreas cancer.
Original or recent tumor tissue must be available.
Patients must have been off prior chemoptherapy for 4 weeks and radiation for 3 weeks.
Patients must have adequate renal, liver, and bone marrow function, not have serious infection or life-threatening illness (unrelated to tumor).
Must be able to swallow capsules and not have gastrointestinal disorders that may affect absorption of the drug.

Exclusion criteria